Strontium ranelate 135459-87-9

Melting point > 310 ° C (dec.)

Storage conditions - 20 ° C Freezer

Solubility H2O: soluble1mg/mL, clear (generosity)

Powder form

Color: white to beige

Strontium ranelate is a drug for osteoporosis, which is white to yellowish-white powder or crystalline powder, odorless, slightly soluble in water, almost insoluble in ethanol and soluble in dilute hydrochloric acid. Fujisawa pharmaceutical has the right to develop, produce and sell the product in Japan. Clinically, it is mainly used for the treatment and prevention of osteoporosis in postmenopausal women, significantly reducing the risk of vertebral fracture and hip fracture.

Strontium ranelate has dual pharmacological effects of inhibiting bone resorption and promoting bone formation. On the one hand, in cells enriched with osteoblasts, the synthesis of collagen and non-collagen can be increased, and the osteoblast-mediated bone formation can be promoted by enhancing the proliferation of pre-osteoblasts. On the other hand, by reducing osteoclast differentiation and resorption activity, bone resorption can be reduced, so that bone regeneration can be rebalanced, which is conducive to bone formation.